Tocqueville Asset Management L.P. increased its holdings in shares of bluebird bio Inc (NASDAQ:BLUE) by 2.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 54,760 shares of the biotechnology company’s stock after buying an additional 1,415 shares during the quarter. Tocqueville Asset Management L.P. owned 0.10% of bluebird bio worth $7,995,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also modified their holdings of the company. Stratos Wealth Partners LTD. purchased a new position in shares of bluebird bio during the third quarter valued at $106,000. NuWave Investment Management LLC grew its holdings in shares of bluebird bio by 10,811.1% during the third quarter. NuWave Investment Management LLC now owns 982 shares of the biotechnology company’s stock valued at $143,000 after buying an additional 973 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. grew its holdings in shares of bluebird bio by 635.0% during the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,154 shares of the biotechnology company’s stock valued at $167,000 after buying an additional 997 shares in the last quarter. Tower Research Capital LLC TRC purchased a new position in shares of bluebird bio during the second quarter valued at $201,000. Finally, SG Americas Securities LLC purchased a new position in shares of bluebird bio during the third quarter valued at $214,000.
BLUE has been the topic of a number of research analyst reports. Morgan Stanley lowered their price target on bluebird bio from $190.00 to $186.00 and set an “equal weight” rating on the stock in a report on Monday, October 15th. Cantor Fitzgerald set a $122.00 price target on bluebird bio and gave the company a “sell” rating in a report on Thursday, August 23rd. ValuEngine upgraded bluebird bio from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 2nd. BidaskClub downgraded bluebird bio from a “sell” rating to a “strong sell” rating in a report on Tuesday, October 23rd. Finally, Goldman Sachs Group downgraded bluebird bio from a “conviction-buy” rating to a “buy” rating in a report on Friday, September 21st. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and seventeen have assigned a buy rating to the stock. bluebird bio has a consensus rating of “Buy” and an average target price of $194.80.
In other news, COO Susanna Gatti High sold 1,890 shares of the company’s stock in a transaction dated Monday, December 3rd. The stock was sold at an average price of $113.83, for a total transaction of $215,138.70. Following the completion of the sale, the chief operating officer now owns 15,610 shares in the company, valued at approximately $1,776,886.30. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director James Mandell sold 1,000 shares of the company’s stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $150.77, for a total value of $150,770.00. Following the sale, the director now owns 1,568 shares of the company’s stock, valued at approximately $236,407.36. The disclosure for this sale can be found here. Insiders sold 21,490 shares of company stock worth $2,901,186 in the last 90 days. Corporate insiders own 3.00% of the company’s stock.
Shares of NASDAQ BLUE opened at $102.23 on Friday. bluebird bio Inc has a one year low of $100.99 and a one year high of $236.17. The stock has a market capitalization of $5.95 billion, a price-to-earnings ratio of -13.26 and a beta of 2.37.
bluebird bio (NASDAQ:BLUE) last issued its earnings results on Thursday, November 1st. The biotechnology company reported ($2.73) EPS for the quarter, beating analysts’ consensus estimates of ($2.90) by $0.17. bluebird bio had a negative return on equity of 31.50% and a negative net margin of 1,326.02%. The firm had revenue of $11.50 million for the quarter, compared to the consensus estimate of $6.90 million. During the same quarter in the previous year, the company posted ($1.73) earnings per share. The business’s quarterly revenue was up 49.2% compared to the same quarter last year. As a group, equities research analysts forecast that bluebird bio Inc will post -10.71 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2018/12/08/bluebird-bio-inc-blue-shares-bought-by-tocqueville-asset-management-l-p.html.
bluebird bio Company Profile
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.
Further Reading: How is Preferred Stock Different from Common Stock?
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio Inc (NASDAQ:BLUE).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.